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as posted on the Board's Web site. However, at this writing,
the most recent newsletter available on the Board's Web site
dates back to 1997. According to EO Ollinger, DCA must
first approve all Web site postings; apparently the new news-
letter was misplaced for some time in DCA bureaucracy, but
is now back on track and should be electronically posted in
the near future.
At its December 2000 meeting, the Board unanimously
reelected Gerald Easton, OD, as Board president and Sheilah
Titus, OD, as vice president. Steven Grant, OD, was selected
Board secretary.
Due to its failure to muster a quorum, the Board can-
celled its scheduled March 16-17,2001 meeting in Oakland.
FUTURE MEETINGS
2001: June 8-9 in Orange County; September 7-8 in
Sacramento; November 30-December 1 in San Diego.
2002: No meetings have been scheduled at this writing.
Board of Pharmacy
Executive Officer: Patricia Harris + (916) 445-5014 * Internet:www.pharmacy.ca.gov
ursuant to Business and Professions Code section 4000
et seq., the Board of Pharmacy grants licenses and per-
mits to pharmacists, pharmacy interns, pharmacy tech-
nicians, pharmacies, pharmacy corporations, nonresident
pharmacies, wholesale drug facilities, veterinary food-ani-
mal drug retailers, out-of-state distributors, clinics, and hy-
podermic needle and syringe distributors. It regulates all sales
of dangerous drugs, controlled substances, and poisons. The
Board is authorized to adopt regulations, which are codified
in Division 17, Title 16 of the California Code of Regula-
tions (CCR).
To enforce the Pharmacy Law and its regulations, the
Board employs full-time inspectors who investigate complaints
received by the Board. Investigations may be conducted openly
or covertly as the situation demands. The Board conducts fact-
finding and disciplinary hearings, and is authorized by law to
suspend or revoke licenses or permits for a variety of reasons,
including professional misconduct and any misconduct sub-
stantially related to the practice of pharmacy.
The Board of Pharmacy is a consumer protection agency
located within the Department of Consumer Affairs (DCA).
The Board consists of eleven members, four of whom are
public members. The Governor appoints two public mem-
bers and the Senate Committee on Rules and the Speaker of
the Assembly each appoint one. The remaining members are
pharmacists appointed by the Governor, five of whom must
be active practitioners. All Board members are appointed for
four-year terms.
In March 2000, Governor Davis appointed Donald W.
Gubbins, Jr., Pharm.D., to the Board. Dr. Gubbins is Regional
Pharmacy Development Manager for RiteAid Corporation.
In June 2000, the Senate Rules Committee named Will-
iam Powers as a public member of the Board. Powers is leg-
islative director of the Congress of California Seniors and is
also Coordinator of the Capital City Task Force for the Ameri-
can Association of Retired Persons (AARP).
MAJOR PROJECTS VV
State Auditor Critical of Board's
Enforcement System
In April 2001, the Bureau of State Audits (BSA) released
a report entitled Investigations of Improper Activities by State
Employees: July 2000 Through January 2001. In a chapter
entitled Board of Pharmacy: Gross Inefficiency in Process-
ing Consumer Complaints and Failure to Record and Pay
Overtime, BSA noted that it received an allegation that the
Board had a backlog of consumer complaints and was not
doing its job to investigate incoming complaints. BSA inves-
tigated and substantiated the allegation. Specifically, BSA
found that the Board's established timeframes to resolve com-
plaints-up to 290 days for complex complaints and 140 days
for all others-are excessive when compared to the
timeframes mandated by law or regulation for other consumer
protection agencies.
Second, BSA found that the Board fails to meet its own
excessive timeframes. Between January 1, 1994 and March
6, 2000, it took the Board an average of 441 days to close
5,265 complaints. Of those complaints, the Board resolved
only 35% of its high-risk complaints within 290 days and
only 20% of its less complex cases within its 140-day goal.
As of March 6,2000, the Board had not resolved 770 of 1,552
open complaints within its maximum 290-day goal. Although
the Board's goal is to complete the investigation phase of its
enforcement process within five months, BSA found that
Board staff takes on average nine months to complete inves-
tigations after the complaint is assigned to an inspector.
Third, BSA examined the Board's system for prioritiz-
ing complaints. Based on the subject matter of complaints,
the Board categorizes its high-risk complaints as Priority 1
(urgent-immediate), Priority 2 (rapid), Priority 3 (active in-
vestigation), or Priority 4 (standard, consistent turnaround).
BSA found that this system "does not ensure that complaints
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involving potential injury are investigated within the maxi-
mum allowed time of five months." BSA found that, regard-
less of risk, the Board took longer than five months to com-
plete about 60% of its investigations.
Fourth, BSA found that the Board has not maintained
adequate staff to ensure timely complaint resolution. The
Board is authorized to hire only 19 inspectors and two super-
vising inspectors (all of whom are pharmacists) to cover the
entire state of California. In fiscal
year 1999-2000, there was a BSA concluded that "th
35.7% vacancy rate for inspector inefficiency on the part of
and supervising inspector posi- complaints increase th
tions at the Board; 7.5 of the pharmacy laws will con
Board's 21 inspector positions affect the public health, s
were vacant. Had those positions consumers."
been filled, BSA projected that
each inspector would have been
able to resolve an additional 51 complaints per year and a
backlog would not exist. BSA noted that the Board believes
that difference in salary paid to public sector pharmacists
compared with the private sector hinders its ability to attract
qualified applicants for its inspector positions. [17:1 CRLR
66]
Finally, BSA noted that the Board failed to maintain
records adequate to ensure that staff were compensated for
all overtime hours worked, possibly in violation of the fed-
eral Fair Labor Standards Act_
BSA concluded that "these IOM reviewed the results
concerns reflect gross inefficiency conducted in Colorado and
on the part of the Board. Delays York-and found that up to!
in resolving complaints increase year due to medical errors.
the risk that those violating phar-
macy laws will continue to make
mistakes that affect the public health, safety, or welfare of
California consumers."
In a written response, the Board agreed it had not inves-
tigated and completed cases promptly in the past, and stated
that it is taking action to address these concerns. The Board
said that it is focusing on clearing away the existing backlog
of cases (and is down to 393 pending complaints more than
six months old as of March 8, 2001) and will then be better
able to prioritize the remaining complaints. The Board noted
that it has increased its salaries for pharmacists, hired eight
inspectors and one supervising inspector during the seven
months prior to January 2001, and expects to fill the remain-
ing three vacant inspector positions soon. The Board also
stated it plans to increase consumer awareness by adding a
toll-free consumer complaint line and posting this number in
every pharmacy later in 2001.
Prevention of Medication Errors:
Quality Assurance Program
For several years, the Board has attempted to address the
growing incidence of medication errors, which can include
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drug for a patient's condition; (2) a pharmacist enters incor-
rect information on the label of the prescription container;
(3) a prescription is dispensed with the wrong drug or wrong
drug dosage; (4) a drug is dispensed that is contraindicated if
taken with another drug; or (5) a prescription is filled with a
medication whose expiration date has passed. Obviously, a
medication error can result in patient injury or death. To pre-
vent such harm, the Board initiated rulemaking in July 1999
to require every licensed phar-
e concerns reflect gross macy to develop and implement
 Board. Delays in resolving a quality assurance program
risk that those violating (QAP) to document medication
ue to make mistakes that errors attributable to the phar-
ety, or welfare of California macy or its personnel. After an
October 1999 public hearing at
which many pharmacists and rep-
resentatives of pharmacies, retail-
ers, and pharmaceutical companies registered opposition to
the QAP requirement, the Board unanimously deferred the
issue and remanded it to its Enforcement Committee for fur-
ther study. [17:1 CRLR 57-58; 16:2 CRLR 55]
Although the Board took no further action with respect
to its proposed rulemaking, the issue came to a crux with the
Institute of Medicine's (IOM) November 1999 publication
of To Err Is Human: Building a Safer Health System, in which
IOM reviewed the results of two large studies-one conducted
in Colorado and Utah and the
f two large studies-one other in New York-and found
Utah and the other in New that up to 98,000 Americans die
98,000 Americans die each each year due to medical errors.
According to IOM, "medication
errors alone, occurring either in
or out of the hospital, are esti-
mated to account for over 7,000 deaths annually." Extrapo-
lated to California, the statistics revealed by IOM indicate
that over one million adverse drug reactions occur each year
in California on an outpatient basis alone. A great many of
these reactions are preventable medication errors that inflict
pain, loss of function, and economic loss on consumers. Thus,
instead of rulemaking, the Board decided to sponsor legisla-
tion, SB 1339 (Figueroa), which was enacted and requires
pharmacies to implement a QAP by January 1, 2002 (see 2001
LEGISLATION). Each pharmacy's QAP must, at minimum,
document medication errors attributable in whole or in part
to that pharmacy or its personnel. SB 1339 also requires the
Board to adopt regulations to implement the program by Sep-
tember 1,2001.
On February 23, 2001, the Board published notice of its
intent to adopt new section 1711, Title 16 of the CCR, to
implement SB 1339. Section 1711 would require each phar-
macy- effective January 1, 2002-to establish and maintain
a QAP designed to prevent medication errors. As published,
section 1711 (b) would define the term "medication error" to
mean "any act or omission in the dispensing process that may
cause or lead to patient harm." It does not include any act or
o
9
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omission that is corrected prior to furnishing the drug to the
patient or patient's agent. Section 17 11 (c) would require each
pharmacy's QAPto be "described in written policies and pro-
cedures maintained in the pharmacy," which must include
"directions for communicating the details of the error to the
patient, caregiver, prescriber, and other members of the health
care team as appropriate. This communication shall also de-
scribe methods for correcting the error and/or reducing its
negative impact on the patient."
The QAP must be reviewed by the Numerous witnesses re
licensee and revised if necessary pharmacies testified th
prior to application for renewal of regulations is punitive rat
the pharmacy's license, pharmacy personnel wh
As published, section 1711(d) Board will not be encou
would require each QAP to in- result is punitive.
clude a process designed to detect
and identify medication errors.
"An investigation of each medication error shall commence
as soon as is reasonably possible, but no later than two busi-
ness days from the date the medication error is discovered. If
the investigation indicates that the medication error is attrib-
utable, in whole or in part, to the pharmacy or its personnel, a
quality assurance review shall be performed." Under proposed
section 1711(e), the quality assurance review shall include
investigation of the error and completion of an "essential cause
examination" of the error (defined in subsection (f) to focus
primarily on "systems and processes, not individual perfor-
mance"). A written record of the quality assurance review,
which must be retained in the pharmacy, must include (1) the
date of, location, and participants in the quality assurance
review conducted; (2) a record of the facts relating to the
medication error; (3) the essential cause examination; (4) the
findings and determinations generated by the quality assur-
ance review; (5) changes to pharmacy policy or procedure
made pursuant to the quality assurance review; and (6) ac-
tivities undertaken with the patient or other healthcare pro-
viders to mitigate the error.
Subsection (g) of the proposed regulation would require
pharmacies to keep records relating to activities undertaken
as part of a quality assurance review in the pharmacy for at
least three years from the date those records were created.
The Board may review quality assurance records in an indi-
vidual pharmacy "as necessary to protect the public health
and safety, or if fraud is alleged by a government agency with
jurisdiction over the pharmacy." As set forth in SB 1339, pro-
posed section 1711(h) provides for confidentiality of QAP
records: "Neither the proceedings nor records of a pharmacy's
quality assurance program shall be subject to discovery in
any arbitration, civil, or other proceeding" except as provided
in subsection (g) as to the Board. Further, "no person in at-
tendance at a meeting of a pharmacy's quality assurance com-
mittee shall be required to testify in any arbitration, civil, or
other proceeding" as to what transpired at that meeting, ex-
cept as provided in subsection (g) as to the Board. Subsec-
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1711 may be considered by the Board as a mitigating factor
in its investigation and evaluation of a medication error.
On April 26, 2001, the Board held a public hearing on
the proposed QAP regulations. Numerous witnesses repre-
senting pharmacists and pharmacies testified that the overall
effect of the regulations is punitive rather than educational,
and that pharmacy personnel who are already fearful of the
Board will not be encouraged to report errors if the result is
punitive; these witnesses advo-
senting pharmacists and cated softening of the regulatory
the overall effect of the language to promote a "blame-
than educational, and that free, sanction-free, non-punitive"
are already fearful of the approach that seeks to avoid rep-
led to report errors if the etition of errors. In particular, they
complained about the focus on the
"essential cause examination,"
the definition of the term "medi-
cation error," and the length of time that QAP records must
be retained in the pharmacy.
Following much testimony, the Board agreed to adopt
section 1711 subject to several amendments. First, the Board
revised subsection (b)'s definition of the term "medication
error" to "any variation from a prescription or drug order not
authorized by the prescriber." Under this definition, a "medi-
cation error" does not include any variation that is corrected
prior to furnishing the drug to the patient or patient's agent or
any variation that is allowed by law (such as form variations
contemplated under SB 340 (Speier); see 2001 LEGISLA-
TION). Further, the Board deleted the requirement that the
QAP include procedures for communicating the details of the
error to the patient, caregiver, prescriber, and other members
of the health care team, and substituted language requiring
communication about the error with the patient and prescriber
only "when a medication error threatens a patient's well-be-
ing." The Board also deleted entirely subsection (f) (defining
the "essential cause examination"), deleted the requirement
in subsection (e) that the quality assurance review include an
"essential cause examination," and substituted language re-
quiring the review to include "a determination of the proxi-
mate cause of the medication error" and "an evaluation of the
systems and processes that may have contributed to the medi-
cation error." The Board also reduced the QAP records reten-
tion requirement in subsection (g) to one year. The Board
agreed to release the modified language of section 1711 for
an additional 15-day comment period, and is expected to re-
visit this proposed regulation at its July 2001 meeting.
Board Revises Disciplinary Guidelines
At its October 2000 meeting, the Board held an informa-
tional hearing on proposed changes to its 1997 disciplinary
guidelines, which essentially set forth every statute and regu-
lation the violation of which is grounds for disciplinary ac-
tion by the Board, and identify the Board's preferred penalty
for that violation. Like other regulatory agencies, the Board
developed disciplinary guidelines to guide licensees, attor-
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neys who prosecute disciplinary cases, administrative law
judges who preside over disciplinary hearings, and the Board
itself in disciplinary decisionmaking; the intent of the guide-
lines is to establish consistency in disciplinary penalties for
similar offenses on a statewide basis. Prior to its October 2000
meeting, the Board drafted revisions to the 1997 guidelines
to correct errors, make changes due to amendments to the
Pharmacy Law and the Board's regulations since 1997, and
reorder the various sections into a document that is more user-
friendly. No comments were submitted or received.
Thus, on December 1, 2000, the Board published of its
notice of intent to amend section 1760, Title 16 of the CCR,
which requires the Board-in reaching a disciplinary deci-
sion-to consider its 1997 disciplinary guidelines. The guide-
lines are not in section 1760; they are simply incorporated by
reference. The Board proposed to amend section 1760 to re-
quire consideration of the new version of the guidelines (to
be dated January 2001) which were the subject of the Octo-
ber 2000 informational hearing.
At its January 2001 meeting, the Board held a public
hearing on its proposal to amend section 1760. The Califor-
nia Pharmacists Association, Longs Drug Stores, and an at-
torney submitted comments. Following the hearing, the Board
voted to adopt the revised version of the disciplinary guide-
lines subject to the following changes: (1) deletion of a pro-
vision stating that failure to pay cost recovery is grounds for
automatic revocation (with no hearing); (2) a minor change
in a provision regarding the tolling of probation; (3) the addi-
tion of a provision prohibiting a suspended or revoked phar-
macist from performing the duties of a pharmacy technician
or an exemptee for any entity licensed by the Board; and (4)
deletion of a provision requiring a pharmacy on probation to
post a notice of the probation in the pharmacy premises. Sub-
ject to those changes to the disciplinary guidelines, the Board
adopted the proposed amendment to section 1760. At this
writing, DCA is considering the rulemaking file on section
1760; after DCA approves the file, it will be forwarded to the
Office of Administrative Law (OAL) for approval.
Self-Assessment of a Pharmacy by the
Pharmacist-In-Charge
On December 1,2000, the Board published its notice of
intent to amend section 1715, Title 16 of the CCR, which
established a "self-assessment" program effective January 1,
1999, under which pharmacists-in-charge must complete a
self-assessment of the pharmacy's compliance with federal
and state pharmacy laws by March 31 of every odd-numbered
year. The primary purpose of the self-assessment is to pro-
mote compliance with the law through self-examination and
education. The Board developed two forms to guide a
pharmacist's self-assessment: Form 171-29 for community
pharmacies, and Form 171-30 for hospital inpatient pharma-
cies. [16:1 CRLR 76]
The proposed amendments to section 1715 would move
the biennial completion date of the self-assessment process
from March 31 to July 1 of each odd-numbered year, and
would incorporate by reference new January 2001 versions
of the two forms on which the self-assessment must be con-
ducted.
At its January 2001 meeting, the Board adopted the pro-
posed amendments. As of April 30, 2001, the Board is await-
ing approval of the proposed amendments by DCA, and has
not yet submitted them to OAL for approval.
Preprinted, Multiple Checkoff Prescription Blanks
On August 25, 2000, the Board published its notice of
intent to amend section 1717.3(b), Title 16 of the CCR, which
currently prohibits pharmacists from dispensing controlled
substances and/or more than one dangerous drug from a "pre-
printed, multiple checkoff prescription blanks," defined as
any form used or intended to be used as a written order for an
individual for dangerous drugs which order contains or lists
more than one drug for which the name, strength, amount, or
quantity has been preprinted on the prescription blank. Un-
der this version of the regulations, a prescriber must use one
completed blank for each drug he/she is prescribing for a pa-
tient, regardless of whether most or all of the drugs being
prescribed are preprinted on the form. This regulation was
originally written to assure that patients would not mark ad-
ditional prescription drugs prior to submitting the prescrip-
tion document to the pharmacy.
However, the use of preprinted prescription blanks has
proven to eliminate confusion as well as reduce potential
medication errors. To facilitate the use of preprinted, mul-
tiple checkoff prescription blanks by prescribers, the Board
proposes to amend section 1717.3(b) to allow a pharmacist
to dispense more than one dangerous drug from a preprinted,
multiple checkoff prescription blank provided that the pre-
scriber indicates on the form the total number of drugs se-
lected.
The 45-day comment period ended October 9, 2000, and
the Board held no public hearing on the proposal. At its Janu-
ary 25,2001 meeting, the Board adopted the proposed amend-
ment. At this writing, DCA is considering the rulemaking file
on section 1717.3(b); once DCA approves the file, it will be
forwarded to OAL for approval.
Update on Other Board Rulemaking
The following is an update on recent Board rulemaking
proceedings described in detail in Volume 17, No. 1 (Winter
2000) of the California Regulatory Law Reporter:
* Citation and Fine Regulations. In July 1999, the Board
amended sections 1775 and 1775.1, Title 16 of the CCR, to
expand the list of violations which are grounds for a citation
and/or fine to include noncompliance with the Board's con-
tinuing education requirements and violation of the Board's
regulations, and to update the statutory references in the sec-
tions to reflect the 1996 reorganization of the Pharmacy Law.
[17:1 CRLR 60] OAL approved the amended regulations on
March 1, 2000.
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In the meantime, the Board continued its discussion of
staff's proposal to expand its rather narrow citation and fine
regulations to permit the issuance of citations and fines for
other violations, and to permit the Board's executive officer
to issue citations and fines for certain violations. Whereas
the executive officers of other DCA agencies are routinely
permitted to issue citations and fines, section 1775 limits the
issuance of citations and fines to "a board inspector or com-
mittee of the board." [17:1 CRLR 601
On May 12, 2000, the Board published its intent to amend
sections 1775 and 1775.2, repeal section 1775.1, and adopt
new section 1775.15, Title 16 of the CCR, to expand its use
of the citation and fine sanction and to permit its executive
officer to issue citations and fines
in certain cases. In its initial state- In its initial statement
ment of reasons justifying the pro- proposed regulations, the
posed regulations, the Board numbers of complaints
stated that "increasing numbers of increase since 1995) a
complaints against licensees" (a achieving licensee comp
10% increase since 1995) and "on- requirements" demon.,
going difficulties in achieving lic- enforcement options.
ensee compliance with routine li-
censure requirements" demon-
strate the need for added enforcement options. "Currently,
the Board must choose between admonition (i.e., field admo-
nitions by inspectors, office conferences, and compliance
committee actions) and formal disciplinary action against a
license when imposing sanctions for violations. Current regu-
lations do not provide the Board with appropriate options for
violations that warrant more severe sanction than admoni-
tion but are not appropriate for formal disciplinary
action....Citation and fine provides the Board with an inter-
mediate sanction to increase compliance and expend limited
Board resources more efficiently."
As proposed, section 1775(a) would be amended to elimi-
nate the authority of a Board inspector to issue a citation and/
or fine, but authorize a committee of the board to issue cita-
tions and fines for any violation of the Pharmacy Law or the
Board's regulations. New subsection 1775(d) would require
a committee of the board to meet periodically in both the
northern and southern portions of the state for the purpose of
reviewing alleged violations, including notices of violation
issued by the Board, and issuing citations to licensees of the
Board.
New subsection 1775(d) would authorize the Board to
issue a "request to appear" to individuals before a committee
of the board; the "request to appear" must include a summary
of alleged violations to be reviewed at the hearing. Under the
proposed regulation, "persons or entities may reschedule their
appearance before a committee of the board," but the com-
mittee may issue a citation and impose a fine in the absence
of a person who fails to appear a second time.
The Board also proposed to repeal section 1775.1, which
lists the violations subject to citation and fine, as moot (inas-
much as amended section 1775(a) would permit a committee
of the board to issue a citation and fine for any violation of
the Pharmacy Law or the Board's regulations).
New section 1775.15(a) would permit the Board's ex-
ecutive officer to issue citations and fines for specified viola-
tions of the Pharmacy Law. Under the proposed regulation, the
EO is not pernitted to issue citations and fines to pharmacies
and pharmacists; however, the EO may issue citations and fines
to other Board licensees (including wholesalers, manufactur-
ers, and veterinary food-animal drug retailers) and for viola-
tions relating to hypodermic needles and syringes, continuing
education, and the failure to file a notice of discontinuance of
business. These violations generally relate to the administra-
tive requirements of site permits rather than the provision of
patient care. Section 1775.15(b)
reasons justifying the would permit the executive officer
ard stated that "increasing to issue citations and fines for vio-
ainst licensees" (a 10% lations relating to unlicensed prac-
"ongoing difficulties in tice under Business and Profes-
ice with routine licensure sions Code section 148.
ate the need for added Section 1775.2 would be
amended to conform to the above-
described changes, and would re-
quire a committee of the board
and the executive officer-in assessing the amount of an ad-
ministrative fine- to consider the number of violations found
in the investigation, in addition to other factors already listed
in section 1775.2.
On July 25,2000, and over the opposition of the Califor-
nia Pharmacists Association and Longs Drug Stores, the Board
adopted these proposals without change. However, at this
writing, the Board has not yet submitted the rulemaking file
on the proposed changes to QAL because the State and Con-
sumer Services Agency declined to sign the fiscal impact state-
ment until the Department of Finance approves a budget
change proposal (BCP) submitted by the Board to carry out
its expanded authority; the BCP was not approved due to the
Governor's limit on the size of growth in state government.
The final day for submission of this rulemaking file to PAL
is May 12, 2001.
Meanwhile, at the Board's December 2000 meeting, the
Enforcement Committee recommended that the Board fur-
ther amend its citation and fine regulations to permit a com-
mittee of the board to issue citations and fines for violations
of the Confidentiality of Medical Information Act, Civil Code
section 56 et seq.; and to Internet pharmacies that dispense
drugs without a prescription issued pursuant to a good faith
examination under SB 1828 (Speier) (Chapter 681, Statutes
of 2000) (see 2000 LEGISLATION). At its January 2001
meeting, the Board approved the Enforcement Committee's
recommendations; at this writing, the Board has not yet pub-
lished those regulatory changes for comment.
* Dangerous Drugs and Devices Exempt From Stor-
age in a Pharmacy. SB 1308 (Committee on Business and
Professions) (Chapter 655, Statutes of 1999) amended Busi-
ness and Professions Code section 4057 to remove from stat-
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ute two lists of dangerous drugs and devices that are exempt
from the Pharmacy Law's requirements and may be stored
outside a pharmacy's licensed premises when furnished to
specified licensed individuals or entities. Instead, SB 1308
directs the Board to list these exempt drugs and devices in
regulation.
In October 1999, the Board published notice of its intent
to adopt section 1714.5,Title 16 of the CCR, to place in regu-
lation two lists of dangerous drugs and devices that are ex-
empt from required storage in a pharmacy, provided they are
obtained by a person or entity meeting specified licensure
and practice criteria. [17:1 CRLR 60-61] During the 45-day
comment period, the Board received several comments which
prompted it to substantially revise the proposed regulation
and republish it in August 2000.
As republished, new section 1714.5 would list danger-
ous drugs and devices that are exempt from storage in a phar-
macy provided that their sale and furnishing is made to a clinic,
hospital, institution, or an establishment holding a currently
valid and unrevoked license or permit under Health and Safety
Code section 1200 et seq. (a hospital, clinic, or other licensed
health facility), Welfare and Institutions Code section 3300
et seq. (the California Rehabilitation Center of the Depart-
ment of Corrections), or Welfare and Institutions Code sec-
tion 6250 et seq. (institutions housing individuals who have
been judicially committed as mentally disordered sex offend-
ers, sexually violent predators, or mentally retarded). The
Board adopted new section 1714.5 at its October 2000 meet-
ing; OAL approved the new section on April 9, 2001, and it
became effective on May 9,2001.
* Offsite Storage of Records. Under various provisions
of the Business and Professions Code, all records of the manu-
facture, sale, acquisition, or disposition of prescription drugs
or devices must be, at all times during business hours, open
to inspection by authorized law enforcement officers. Busi-
ness and Professions Code section 4333 requires pharmacies
to preserve these records at the licensed premises for at least
three years from the making of the records. However, the
Board is authorized to grant a waiver of the requirement that
the records be kept on the licensed premises to an applicant
who requests a waiver.
At its January 2000 meeting, the Board considered-for
the second time-proposed section 1707, Title 16 of the CCR,
which would establish criteria for a waiver of the onsite stor-
age requirement, to enable pharmacists to store records at t
place other than the licensed premises. [17:1 CRLR 59-60]
After discussion at the meeting, the Board modified the lan-
guage and adopted it subject to a 15-day comment period.
Under the modified language, the Board "shall" grant a waiver
of the onsite storage requirement to any licensee for offsite
storage of the records described in Business and Professions
Code subsections 4105(a), (b), and (c) unless the applicant
has, within the preceding five years, failed to produce records
pursuant to section 4081 or has falsified records covered by
section 4081. An entity that is granted a waiver must main-
tain the storage area so that the records are secure (including
from unauthorized access) and must be able to produce the
records within two business days upon the request of the Board
or an authorized law enforcement officer. In the event that a
licensee fails to comply with these conditions, the Board may
cancel the waiver without a hearing, and the licensee must
maintain all records at the licensed premises. Further, even
under this waiver, all prescription records for noncontrolled
substances must be maintained on the licensed premises for
one year from the date of dispensing; and all prescription
records for controlled substances must be maintained on the
licensed premises for two years from the date of dispensing.
Section 1707 also expressly permits licensees to store the
records described in subdivisions (a), (b), and (c) of section
4105 of the Business and Professions Code in a storage area
at the same address or adjoining the licensed premises with-
out obtaining a waiver from the Board if the records are readily
accessible to the pharmacist-in-charge (or other pharmacist
on duty, or exemptee) and upon request to the Board or any
authorized law enforcement officer, and the storage is main-
tained so that the records are secure and so that the confiden-
tiality of any patient-related information is maintained. OAL
approved the regulation on September 20, 2000; it became
effective on October 20, 2000.
* Specialized Refill Pharmacies. In May 1999, the Board
adopted section 1707.A, Title 16 of the CCR, to set standards
for a "refill pharmacy," which prepares refill prescriptions for
another pharmacy. New section 1707.4 allows a pharmacy to
utilize the services of another pharmacy to provide its refills if
it has a contract for these services or has common ownership
with the refill pharmacy; specifies the labeling requirements
for a prescription refilled at a refill pharmacy, including the
name and address of the refill pharmacy and/or the name and
address of the pharmacy which receives the refilled prescrip-
tion for dispensing to the patient, and information as to which
pharmacy the patient should contact if he/she has questions
(this information may be either on the label or in writing ac-
companying the medication); specifies the documentation re-
quirements for the originating pharmacy and the refill phar-
macy; and allows a pharmacy to operate as a refill pharmacy
as well as fill new prescriptions. [17:1 CRLR 61]
OAL disapproved section 1707.4 on January 24, 2000
for technical reasons. On April 7, 2000, the Board mailed a
15-day notice clarifying the steps taken to modify its origi-
nally proposed language and resubmitted the modified sec-
tion for approval. OAL approved section 1707.4 on June 1,
2000; it became effective on July 1, 2000.
* Pharmacy Operations During Temporary Absence
of a Pharmacist. SB 188 (Leslie) (Chapter 900, Statutes of
1999) requires the Board to adopt regulations accommodat-
ing the temporary absence of a pharmacist from a pharmacy.
SB 188 and the new regulations became necessary after the
Governor signed SB 651 (Burton) (Chapter 190, Statutes of
1999), which mandates breaks and lunch periods for phar-
macists during the workday. Absent new regulations, the
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combination of SB 651 and the existing Pharmacy Law would
have required the closure of a single-pharmacist pharmacy and
the removal of all non-pharmacist personnel from the phar-
macy area during the pharmacist's breaks and lunch periods.
At its October 20, 1999 meeting, the Board adopted sec-
tion 1714.1, Title 16 of the CCR, on an emergency basis, to
specify security requirements for prescription drugs and the
limited functions that non-pharmacist staff, such as pharmacy
technicians and assistants, may perform when the pharmacist
is temporarily absent from a single-pharmacist pharmacy.
[17:1 CRLR 58-591 OAL approved the Board's emergency
regulation on December 21, 1999, and it became effective on
January 1,2000.
On November 19, 1999, the Board published notice of
its intent to permanently adopt a slightly modified version of
section 1714.1. Following a January 26, 2000 public hearing
on the proposed regulation, the Board adopted new section
1714.1. The section provides that, in any single-pharmacist
pharmacy, the pharmacist may leave the pharmacy tempo-
rarily for breaks and meals pursuant to section 512 of the
Labor Code and the orders of the Industrial Welfare Com-
mission without closing the pharmacy and removing ancil-
lary staff from the pharmacy only if the pharmacist reason-
ably believes that the security of the dangerous drugs and
devices will be maintained in his/her absence. If the pharma-
cist determines that the pharmacy should close during his/her
absence, then the pharmacist must
close the pharmacy and remove all
ancillary staff (including intern spnar 2 ep
pharmacists, pharmacy techni- sponsor a legislative pro
cians, pharmacy technician train- program permanent an
ees, and nonlicensed personnel) prescription program.
from the pharmacy during his/her
absence. During the pharmacist's temporary absence, no pre-
scription medication may be provided to a patient or a patient's
agent unless the prescription medication is a refill medica-
tion that the pharmacist has checked, released for furnishing
to patients, and does not require a pharmacist's consultation.
During the pharmacist's temporary absence, ancillary
staff may continue to perform the non-discretionary duties
authorized by the Pharmacy Law. These duties must be re-
viewed by the pharmacist upon his/her return. During the
pharmacist's temporary absence, an intern pharmacist may
not perform discretionary duties nor otherwise act as a phar-
macist. The temporary absence authorized by section 1714.1
is limited to that authorized by section 512 of the Labor Code,
and any meal is limited to 30 minutes. Finally, the pharmacy
must have written policies and procedures regarding the op-
erations of the pharmacy during the temporary absence of
the pharmacist for breaks and meals; these policies must in-
clude the authorized duties of ancillary staff, the pharmacist's
responsibility for checking all work performed by ancillary
staff, and the pharmacist's responsibility for maintaining the
security of the pharmacy. These policies must be open to in-
spection by the Board at all times during business hours.
OAL approved new section 1714.1 on June 12,2000 and
it became effective the same day.
* Medical Device Retailer Location Restrictions. In
May 1999, the Board adopted new section 1748.3, Title 16
of the CCR, which explicitly prohibits a medical device re-
tailer from conducting business from a private residence and
from locating a warehouse, the primary purpose of which is
storage of medical devices, at a private residence. [17:1
CRLR 61] OAL approved the regulation on December 17,
1999.
CURES Update
The Controlled Substance Utilization Review and Evalu-
ation System (CURES), established by the Board and the state
Department of Justice (DOJ) under Health and Safety Code
section 11165, electronically monitors the prescribing and dis-
pensing of Schedule II controlled substances by all practitio-
ners authorized to prescribe or dispense them. Currently, the
electronic CURES and the traditional paper-based triplicate
prescription system coexist, and their comparative efficien-
cies are being monitored by the Board and DOJ on a pilot
project basis until July 1,2003. [17:1 CRLR 64; 16:2 CRLR
48-49; 16:1 CRLR 69-70]
At its January 2000 meeting, the Board voted to sponsor
a legislative proposal to make the CURES program perma-
nent and to repeal the triplicate prescription program. On Feb-
ruary 4, 2000, the Board hosted a
CURES conference, formally
ting, the Board voted to known as the "Conference on the
posal to make the CURES Monitoring and Regulation of
to repeal the triplicate Schedule II Controlled Sub-
stances." The idea for the confer-
ence originated from a working
group made up of representatives from state regulatory agen-
cies that work on prescription drug diversion cases, and that
want to improve the CURES program. The agencies involved
include the Board of Pharmacy, the Medical Board, the Den-
tal Board, the Department of Health Services, and DOJ. Na-
tional experts on pain management, controlled substance
monitoring, and drug diversion attended the conference, as
well as doctors, patients, law enforcement officials, patient
advocates, and legislative staff. Discussion focused on
California's monitoring system, which currently includes both
the triplicate prescription forms and the electronic monitor-
ing system under CURES. Despite differences of opinion
among many who attended, the conference culminated in sev-
eral agreements, including (1) the need to make the CURES
program permanent, (2) the need to add the ability to make
patient profile data generated from CURES available to treat-
ing physicians, and (3) the need to repeal the triplicate pre-
scription requirement for Schedule II drugs.
The agreements reached at the conference resulted in the
Board's sponsorship of AB 2018 (Thomson) in 2000. Under
AB 2018 as introduced on February 18, 2000, the triplicate
prescription program would end and the CURES electronic
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system of tracking the prescription of Schedule II narcotics
would become permanent on July 1, 2003. Despite strong
support for the bill by numerous licensing agencies and health
care trade associations and organizations, the bill was opposed
by the Attorney General's Office, numerous law enforcement
agencies, and ultimately the U.S. Department of Justice, all
of whom argued that the triplicate prescription program en-
ables law enforcement to monitor the prescribing of danger-
ous drugs and to minimize the chances of those drugs being
diverted into the illegal market. They further contended that
the CURES system is not secure-they believe it can be com-
promised by entering false or incorrect data. Furthermore,
the law enforcement community argued that the triplicate
prescription program should continue to serve as a check
against CURES being compromised. Due to this heavy op-
position by law enforcement, AB 2018 was substantially
amended in June 2000 in the Senate; as ultimately enacted, it
eases some existing restrictions on the prescription and dis-
pensation of Schedule II drugs to "ease the administrative
hassle" of the triplicate program for prescribers and pharma-
cists (see 2000 LEGISLATION).
Currently, the Board supports SB 1000 (Johannessen),
which would extend CURES until January 1, 2007, state the
legislature's intent that CURES ultimately replace the tripli-
cate program, and require DOJ to prepare a report describing
how CURES would have to be modified in order to make it a
secure stand-alone electronic monitoring system. SB 1000
would also provide additional funding for CURES (see 2001
LEGISLATION).
Use of NAPLEX Exam
In 2000, the Board considered using the North American
Pharmacists Licensure Examination (NAPLEX) of the Na-
tional Association of Boards of Pharmacy (NAPB) as the li-
censing examination for pharmacists in California; use of this
exam, which is administered in every other state, will stimu-
late reciprocity licensure of out-of-state pharmacists and may
help alleviate the pharmacist shortage in California. In Octo-
ber 2000, the Board initiated a review of the NAPLEX by
contracting with DCA's Office of Examination Resources
(OER) to conduct an audit of the NAPLEX. The OER audit
consisted of a psychometric evaluation by a five-member
team, including four psychometricians from California, Colo-
rado, Michigan, and Wisconsin. The fifth member was Board
member and Licensing Committee Chair Holly Strom. The
cost of the audit is projected at approximately $10,000.
On March 22-23, 2001, the audit team met with NAPB
representatives in Illinois and reviewed documentation describ-
ing the examination validation process undertaken by NAPB,
including documentation regarding the occupational analysis,
test plan (blueprint) examination development process, admin-
istration procedures, passing score study, and reliability analy-
ses. At this writing, the next meeting of the audit team is set for
May 2-3, 2001. Upon completion of the audit, the team will
make recommendations to the Board regarding the legal valid-
ity and defensibility of NAPLEX as a California licensure exam
for pharmacists. The team will also prepare a report describing
the extent of the relationship of NAPLEX to the 1999 Stan-
dards for Educational and Psychological Testing of the Ameri-
can Educational Research Association, American Psychologi-
cal Association, and National Council on Measurement in Edu-
cation. The final report will be completed by June 30, 2001
and presented to the Board at its July 2001 meeting.
"Notice to Consumers" Poster
At the Board's July 2000 meeting, the Communications
and Public Education Committee reported completion of a
telephone survey of consumers to measure the effectiveness
of the Board's public education program. The survey (which
was conducted by an outside contractor and required by the
Department of Finance before that agency would approve any
further funding for the Board's public education program)
measured the public's awareness and opinions about the Board
and the importance of medication compliance and consulting
with pharmacists about medications. The survey indicated that
consumers hold a generally positive view of pharmacists and
the role they play in patient care. However, over 75% of those
surveyed had never heard of the Board of Pharmacy, although
92% thought such an entity would be useful or essential to
protect the public. Of those responding that they had heard of
the Board, many believed that the Board represents the inter-
ests of pharmacists. Most respondents stated that the Board
should place posters and pamphlets directly in pharmacies in
order to be more effective in providing consumers with edu-
cational information. As a result of this survey, the Board
voted to update its "Notice to Consumers" poster that is re-
quired to be posted in pharmacies under Business and Pro-
fessions Code section 4122, to better communicate the Board's
role of public protection and education.
At its September 28, 2000 meeting, the Communications
and Public Education Committee discussed the contents of
the "Notice to Consumers" poster, and noted that it had not
been updated since 1993. Because the contents of the poster
are contained in section 1707.2(0, Title 16 of the CCR, the
Board will need to engage in rulemaking to alter the poster.
The Committee decided to recommend that the Board con-
duct rulemaking in 2001 to update and redesign the poster,
and to amend its contents to include questions that consum-
ers should ask their pharmacist about their prescription drug
(such as how and when the patient should take a particular
drug, for how long, what foods and drinks to avoid while
taking the medication, possible side effects, whether the new
medication will work safely with other prescription and non-
prescription drugs the patient is taking, and whether the phar-
macist has written information about the drug in large print
and in languages other than English). The Committee also
recommended that the Board create a toll-free information
number that should be printed on the poster along with the
Board's Web site address. At its October 18-19, 2000 meet-
ing, the Board approved the Committee's recommendations.
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At its January 5, 2001 meeting, the Communications and
Public Education Committee approved draft language of the
revised poster and decided to hold a special informational
hearing on the new language at the Board's January 24,2001
meeting. The draft language began with the following state-
ment: "California law requires the pharmacist personally to
discuss your prescription medicine with you at no charge, the
first time the medicine is prescribed to you or whenever you
have a question... .Know these answers before taking any pre-
scription medicine." Thereafter followed a series of questions
that consumers are encouraged to ask their pharmacist, along
with a statement that pharmacies are required to provide their
current price of any medicine without obligation. The draft
language also suggested that consumers ask their pharmacist
if the pharmacy has written information on any drug dis-
pensed. In response to the survey findings, the draft language
also included a statement: "The Board of Pharmacy is a con-
sumer protection agency that licenses pharmacists and phar-
macies. If you have questions, please contact us. However,
we are not able to help with in-
quiries involving medicine prices
and insurance disputes." At the January 24, 2001
At the January 24, 2001 in- representatives of the
formational hearing, representa- Aspocition an aer
tives of the California Pharma- opposition to the statement
cists Association and Kaiser oral consultations on new n
Permanente expressed opposition
to the statement that pharmacists must offer oral consulta-
tions on new medications "at no charge." CPhA's John Cronin
stated that no law prohibits pharmacists from charging a fee
for statutorily-required oral consultations. Kaiser
Permanente's Steve Gray stated that many pharmacies have
been successful in getting patients as well as insurance com-
panies to pay for oral consultations, and expressed concern
that the draft language may lead insurance companies to think
they cannot pay for such services.
At its April 12, 2001 meeting, the Committee revised the
draft language to delete the "at no charge" language, shorten
the number of questions posed by the poster, and delete the
suggestion that consumers ask their pharmacists for written
information on drugs dispensed. At its April 25-26, 2001
meeting, the full Board approved the Committee's suggested
language, and instructed staff to commence the rulemaking
proceeding to amend section 1707.2(f), regarding the con-
tents of the "Notice to Consumers" poster, with a public hear-
ing to be held at the Board's July or October 2001 meeting.
Federal Compounding Legislation Invalidated
Throughout 1999, the Board monitored the U.S. Food and
Drug Administration's (FDA) implementation of the FDA
Modernization Act of 1997 (FDAMA), which became effec-
tive in November 1998 and required the FDA to enter into a
memorandum of understanding (MOU) with state boards of
pharmacy regarding the compounding of drugs. Compound-
ing is the process by which a pharmacist mixes ingredients to
create a specialized medication for an individual patient at the
direction of a physician. Section 503A of the FDAMA recog-
nized compounding as an element of the practice of pharmacy
that is to be regulated by the states, and distinguished it from
"manufacturing" (which falls within the jurisdiction of the
FDA). The statute instructed the FDA to utilize the MOU to
obtain state agreement on two issues: (1) protocols for the ap-
propriate investigation of complaints relating to compounded
drug products shipped out-of-state; and (2) establishment of
appropriate restrictions on the amount of compounded drugs
shipped in interstate commerce, including "safe harbors" for
pharmacists who distribute compounded products in interstate
commerce. In January 1999, the FDA published a draft MOU
that was the subject of much critical commentary by compound-
ers and state boards; in July 1999, the Board agreed to send a
letter to FDA objecting to several aspects of the MOU. [17:1
CRLR 62-63; 16:2 CRLR 51; 16:1 CRLR 71-721
Before the FDA could finalize the MOU, however, a fed-
eral district court and then the U.S. Ninth Circuit Court of
Appeals invalidated provisions of
hearing, the FDAMA that restrict the right
informational harist of compounding pharmacies to ad-
alifornia Pharmacists vertise the kinds and classes of
permanente expressed drugs they compound; the court
at pharmacists must offer also found that the advertising re-
edications "at no charge." strictions are not severable from
the other provisions of the
FDAMA, such that the entire statute is unconstitutional (see
LITIGATION). As such, pharmacy compounding regulation
is in an unsettled state.
2000 LEGISLATION
SB 1339 (Figueroa), as amended August 8, 2000, re-
quires every pharmacy, on and after January 1, 2002, to es-
tablish a quality assurance program (QAP) that, at minimum,
documents medication errors attributable in whole or in part
to that pharmacy or its personnel. This bill provides that
records generated and maintained for the QAP are not sub-
ject to discovery in arbitration, civil actions, or other pro-
ceedings, except as specified. SB 1339 further provides that
its provisions shall not prohibit a patient from accessing his/
her own prescription records. SB 1339, which also requires
the Board to adopt regulations by September 1, 2001 speci-
fying the requirements and implementation of QAPs, was
sponsored by the Board (see MAJOR PROJECTS). The Gov-
ernor signed SB 1339 on September 24, 2000 (Chapter 677,
Statutes of 2000).
AB 1496 (Olberg), as amended August 25, 2000, de-
letes provisions of the Pharmacy Law authorizing the Board
to license and regulate medical device retailers, and instead
provides for the licensure and regulation of "home medical
device retail facilities," as defined, by the state Department
of Health Services (DHS) effective July 1, 2001. The Gover-
nor signed AB 1496 on September 28, 2000 (Chapter 837,
Statutes of 2000).
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SB 1554 (Figueroa), as amended August 22, 2000, per-
mits a pharmacy to provide dangerous drugs or devices to
certified emergency medical technicians (EMTs) if they are
furnished exclusively for use in conjunction with an ambu-
lance, the dangerous drug or device is within the EMT's scope
of practice, and the EMT provides a written request specify-
ing the name and quantity of the dangerous drugs or devices.
SB 1554 requires records of these transactions to be main-
tained by both the pharmacy and EMT for at least three years.
[16:2 CRLR 51] The Governor signed SB 1554 on Septem-
ber 28, 2000 (Chapter 836, Statutes of 2000).
AB 751 (Gallegos), as amended June 20, 2000, speci-
fies that an existing misdemeanor provision prohibiting any
person from dispensing or furnishing prescription drugs or
devices without a license also applies to any item represented
as, or presented in lieu of, a prescription drug or device. AB
751 also eliminates a January 1, 2001 sunset date on a provi-
sion of law permitting local health officers to take certain
actions against persons selling prescription drugs or devices
without a license, including closing a business upon the sec-
ond offense. This bill was sponsored by Los Angeles County
and is intended to remedy problems associated with
"backroom clinics" and pharmacies that sometimes dispense
substances that are illicit counterfeits and contain no active
ingredients. Governor Davis signed AB 751 on September 7,
2000 (Chapter 350, Statutes of 2000).
AB 2240 (Bates), as amended May 16,2000, eliminates a
requirement that electronic data transmission prescriptions, as
defined, be reduced to writing by the pharmacist, as long as the
pharmacy is able to, for a three-year period following the final
date that the prescription is dispensed, immediately produce a
hard copy report upon request by the Board that includes speci-
fied information. AB 2240 also authorizes prescribers, prescrib-
ers' agents, and pharmacists to electronically enter prescrip-
tions and orders into a pharmacy's or hospital's computer from
an outside location, if permitted by the pharmacy or hospital.
With the approval of the Board and the Department of Justice,
this bill authorizes a pharmacy or hospital to receive electronic
data transmission prescriptions and computer entry prescrip-
tions or orders, for controlled substances in Schedules H through
V, if authorized by federal law and in accordance with regula-
tions promulgated by the U.S. Drug Enforcement Administra-
tion. The Governor signed AB 2240 on September 1, 2000
(Chapter 293, Statutes of 2000).
AB 2018 (Thomson), as amended August 18, 2000, sim-
plifies the triplicate prescription monitoring system for Sched-
ule I controlled substances and revises the information required
in a prescription for a Schedule II controlled substance. Specifi-
cally, the bill lifts the cap on the number of triplicate prescrip-
tions that may be issued to physicians; allows physicians to ei-
ther type the triplicate prescription or have an employee type or
write the prescription, so long as the physician signs the pre-
scription; and permits a pharmacist to fill a Schedule II prescrip-
tion containing error(s) if the pharmacist notifies the prescriber
of the error(s), the prescriber approves any corrections, and the
prescriber faxes or mails a corrected prescription within seven
days of the prescription being dispensed. The Board sponsored
this bill, which-in its original version-would have eliminated
the existing triplicate prescription program and made the CURES
program permanent (see MAJOR PROJECTS). On September
30, 2000,AB 2018 was enacted into law without the Governor's
signature (Chapter 1092, Statutes of 2000).
SB 1828 (Speier), as amended August 11, 2000, adds
section 2242.1 to the Business and Professions Code, which
prohibits the prescription, dispensation, and furnishing of
drugs over the Internet without a prior medical examination,
medical indication, and prescription. Violators are subject to
a $25,000 fine. The Governor signed SB 1828 on September
24, 2000 (Chapter 681, Statutes of 2000).
SB 1903 (Speier), as amended August 29, 2000, applies
provisions of the existing Confidentiality of Medical Infor-
mation Act (CMIA), which generally prohibit health care pro-
viders and contractors from sharing or selling a patient's
medical information, to corporations and their subsidiaries
and affiliates; and specifies that any person or entity seeking
an individual's medical information, other than those specifi-
cally authorized to do so pursuant to the CMIA, must obtain
valid authorization for release of the information. SB 1903
was signed by the Governor on September 30, 2000 (Chapter
1066, Statutes of 2000).
AB 2294 (Davis), as amended August 25, 2000, would
have prohibited the sale or distribution of any dietary supple-
ment product containing ephedrine, unless the product meets
specified requirements; imposed requirements on product la-
bels for dietary supplement products containing ephedrine
group alkaloids; imposed requirements on companies that
engage in direct marketing of any dietary supplement prod-
uct containing ephedrine with respect to advertising and pro-
motional literature; and imposed requirements on manufac-
turers or distributors of dietary supplements containing ephe-
drine group alkaloids with respect to reports of serious ad-
verse effects. Violation of any of these requirements would
be a misdemeanor. On September 29, 2000, Governor Davis
vetoed AB 2294, stating that while regulation and labeling of
dietary supplements containing ephedrine would seem pru-
dent and in the interest of public safety, "this is a matter of
interstate commerce and clearly the responsibility of Con-
gress to regulate, which they have thus far neglected to do."
AB 1791 (Wiggins), as amended August 24, 2000, would
have authorized a pharmacy to furnish epinephrine auto-injec-
tors to a school district or county office of education if certain
conditions are met; authorized the school district or county
office of education to provide emergency epinephrine auto-
injectors to trained personnel, and authorized those trained
personnel to utilize them to provide emergency medical aid to
persons suffering from an anaphylactic reaction. This bill ex-
pressly authorized each public and private elementary and sec-
ondary school in the state to voluntarily determine whether or
not to make emergency epinephrine auto-injectors and trained
personnel available at its school, and to designate one or more
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school personnel to receive prescribed training regarding epi-
nephrine auto-injectors from individuals in specified positions.
On September 28, 2000, Governor Davis vetoed AB 1791. In
his veto message, the Governor acknowledged that the admin-
istration of epinephrine auto-injectors by medically trained
personnel such as school nurses could in certain instances be
life-saving. "However, the shortage of school nurses with the
knowledge necessary to administer medications would assure
that the bulk of school personnel administering epinephrine in
emergencies would be lay personnel. While there are training
programs for non-licensed persons that must administer medi-
cations conducted by schools of nursing, medical schools, and
schools that train physicians assistants, such programs require
weeks for matriculation and cannot safely be compressed into
a few hours. Lay persons cannot receive the necessary back-
ground in a limited training program that would provide the
essential medical judgement skills required to administer medi-
cation in an emergency situation."
SB 550 (Johnston), as amended March 2, 2000, moves
the controlled substance dronabinol (an orally taken pharma-
ceutical form of synthetic medicinal marijuana) from Sched-
ule II to Schedule III, which results in reduced requirements
for the written prescription of the drug (including elimina-
tion of the need to prepare the prescription in triplicate), and
authorizes the oral prescription of the drug. The bill does not
change the criminal penalties attached to unlawful transac-
tions involving dronabinol. The Governor signed SB 550 on
March 29, 2000 (Chapter 8, Statutes of 2000).
The following bills reported in Volume 17, No. 1 (Win-
ter 2000) of the Reporter died in committee or otherwise failed
to be enacted in 2000: AB 660 (Cardenas), a Y2K bill autho-
rizing pharmacists to refill prescriptions between November
1, 1999 and February 29,2000; and SB 404 (Alpert), which
would have authorized pharmacists to initiate emergency con-
traception drug therapy in accordance with protocols estab-
lished by an authorized prescriber. AB 141 (Knox), as
amended March 27,2000, is no longer relevant to the Board.
2001 LEGISLATION
SB 724 (Committee on Business and Professions), as
introduced February 23, 2001, is a DCA omnibus bill that
would make numerous technical clean-up changes to the Phar-
macy Law. Among other things, the bill would revise the defi-
nition of the term "manufacturer"; authorize the Board to es-
tablish a list of dangerous devices that may only be main-
tained, dispensed, sold, or furnished by a pharmacist in a phar-
macy; and revise the Board's authority to issue a temporary
permit to conduct a pharmacy. SB 724 would also provide
that it is a misdemeanor for a wholesaler or any other person
to permit the furnishing of dangerous drugs or dangerous
devices except by a pharmacist or exemptee. The Board is
sponsoring these provisions of SB 724. [S. Appr]
AB 809 (Salinas), as amended April 17,2001, would au-
thorize the installation of secure automated drug delivery sys-
tems (ADDS) in specified clinics licensed by the Board and
located in areas with a pharmacist shortage; these ADDS would
be controlled by pharmacists who may remotely operate these
systems to dispense prescription medication. The bill would
require a pharmacist to review the prescription and the patient
profile, authorize the release of the prescriptions drugs or de-
vices from the automated drug delivery system, and consult
with the patient via a telecommunications link with two-way
audio and video capabilities. AB 809 would further require a
pharmacist to perform the stocking, inventory maintenance,
and review of the operation and maintenance of the system,
and require the Board to adopt regulations specifying other
activities in which a pharmacist operating an ADDS may en-
gage. AB 809 is sponsored by the Board. [A. Appr]
AB 826 (Cohn). Existing law generally restricts phar-
macists to initiating prescriptions and providing clinical ad-
vice in a pharmacy premises; however, under Business and
Professions Code sections 4051 and 4052, a pharmacist is
permitted to provide certain services in licensed acute care
hospitals, health care facilities, home health agencies, or hos-
pice settings. As introduced February 22,2001, AB 826 would
eliminate restrictions on where a pharmacist is permitted to
provide clinical advice, information, or patient consultation'
by removing the language restricting these services to pa-
tients in licensed acute care hospitals, health care facilities,
home health agencies, or hospice settings. The Board is spon-
soring AB 826. IA. Appr]
SB 340 (Speier). Existing law authorizes a pharmacist
filling a prescription order for a drug product prescribed by
the trade or brand name to substitute a generic drug product,
subject to specified requirements. As amended April 17,2001,
SB 340 would additionally authorize a pharmacist to substi-
tute a drug product with a different form of medication hav-
ing the same active chemical ingredients of equivalent strength
and duration of therapy as the prescribed drug product, if the
change is in the patient's best interests and unless the pre-
scriber indicates no substitution may be made. SB 340 would
require that the patient be notified of the substitution.
The Pharmacy Law authorizes specified nonprofit and free
clinics licensed by the Board of Pharmacy to purchase drugs at
wholesale for administration or dispensing to patients registered
for care at the clinic. SB 340 would authorize specified enti-
ties-so-called "340B entities" as defined in federal law-to
contract with a pharmacy to provide pharmacy-related services
to patients of the entity. SB 340 would authorize a pharmacy to
dispense preferentially priced drugs obtained pursuant to fed-
eral law, require that those drugs be segregated from the
pharmacy's other drug stock, and require excess drug stock to
be returned to the distributor. SB 340 would also require phar-
macy records of acquisition and disposition of these drugs to be
kept separate from other records. This bill would exclude 340B
entities and pharmacies from the requirement that they obtain a
wholesaler's license for actions necessary to participate in the
drug purchase program. SB 340 would also provide that it is
unprofessional conduct for any person licensed under the Phar-
macy Law to sell, trade, transfer, or fumish, drugs obtained pur-
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suant to federal law to any person the licensee knows or reason-
ably should know is not a patient of a 340B entity, as defined by
federal law. This bill is sponsored by the Board. [S. Appr]
SB 1000 (Johannessen), as amended April 26, 2001,
would state the legislature's intent to eliminate the triplicate
prescription requirement for Schedule II controlled substances
when a secure stand-alone electronic monitoring system is in
place. This bill would direct the Attorney General to prepare a
report describing how the existing CURES would have to be
modified in order to make it a secure stand-alone electronic
monitoring system (see MAJOR PROJECTS), and require DOJ
to dedicate two employees with peace officer status to investi-
gate persons who improperly prescribe Schedule II controlled
substances. The Board supports SB 1000. [S. Appr]
AB 1589 (Simitian), as amended April 30, 2001, would
require the Medical Board to consult with the Board of Phar-
macy and commission a study that evaluates the electronic
transmission of prescriptions by physicians and report its re-
sults to the legislature by January 1, 2003. The bill would
require MBC's report to include recommendations to encour-
age physicians to use this method to transmit prescriptions
and identify systems to protect patients, including the issu-
ance of a digital certification, as defined. [A. Appr]
AB 536 (Bates). Existing law provides that the ratio of
pharmacy technicians to pharmacists shall not exceed one to
one when the pharmacy technician is assisting the pharma-
cist by the performance of nondiscretionary tasks.As amended
April 18, 2001, AB 536 would increase the maximum ratio
of pharmacy technicians performing specified non-clerical
functions under the direct supervision and control of a phar-
macist to two technicians for each additional pharmacist in
those pharmacies with more than one pharmacist. This ratio
is applicable to outpatient practice settings. AB 536 would
also allow a pharmacist assigned to supervise a second phar-
macy technician to refuse to supervise the technician in speci-
fied circumstances, and would prohibit an employer from
discharging, disciplining, or discriminating against a phar-
macist for doing so. The Board supports AB 536. [A. Appr]
AB 269 (Correa), as amended April 5,2001, would cre-
ate the Division of Enforcement Oversight within DCA. Un-
der the direction of the DCA Director, the Division would
monitor and evaluate the consumer complaint and discipline
system of each DCA board (including the Board). Further,
the bill would require the executive officer of each DCA board
to be appointed by a three-member panel comprised of a rep-
resentative of the board, the DCA Director, and the Governor's
appointments secretary. [A. B&P]
AB 207 (Matthews) as amended April 17, 2001, would
require certain health plans and disability insurers that offer
coverage for prescription drug benefits and that issue identi-
fication cards to enrollees and insureds to issue a card con-
taining uniform information necessary to process claims for
prescription drug benefits. [A. Appr]
AB 108 (Strom-Martin), as amended March 14, 2001,
would require the Board to issue a pharmacy license to au-
thorize the operation of a pharmacy located on Indian trust
lands held by a federally recognized Indian tribe under cer-
tain conditions, including provisions for licensure by the
Board of a pharmacist to be employed by the pharmacy who
is licensed by another state or territory of the United States.
This bill would authorize the Board and a recognized Indian
tribe to enter into a memorandum of agreement concerning
their obligations. AB 108 would also provide that all of the
benefits and obligations of licensure by the Board would ap-
ply to these pharmacies. The Board opposes this legislation
(see RECENT MEETINGS). [A. Health]
AB 258 (La Suer). Under existing law, controlled sub-
stances are categorized into five schedules; the greatest re-
strictions and penalties are placed on those substances con-
tained in Schedule I, which are deemed by law to have no
accepted medical use. The controlled substance gamma-
hydroxybutyrate (GHB)-the so-called "date rape drug"-is
classified as a Schedule II drug. AB 258 would reclassify GHB
from a Schedule II controlled substance to a Schedule I con-
trolled substance, thereby making unlawful the possession,
possession for sale, and sale of GHB punishable under Health
and Safety Code sections 11350(a), 11351, and 11352. The
Board supports AB 258. [A. Appr]
AB 559 (Wiggins), as introduced February 21, 2001, is
Assemblymember Wiggins' reintroduction of AB 1791, which
was vetoed in 2000 (see above). AB 559 would permit school
districts or county offices of education to provide emergency
epinephrine auto-injectors to trained personnel, and permits
trained personnel to utilize these auto-injectors to provide
emergency medical aid to persons suffering from an anaphy-
lactic reaction. The bill would also require the Superinten-
dent of Public Instruction to establish minimum training stan-
dards for the administration of epinephrine auto-injectors;
authorize school nurses or, if a school does not have a nurse,
a person who has received training regarding epinephrine auto-
injectors, to obtain prescriptions for epinephrine auto-injec-
tors and to immediately administer an epinephrine auto-in-
jector under certain circumstances; require those individuals
to initiate emergency medical services or other appropriate
medical follow-up in accordance with written training mate-
rials; and require any school district or county office of edu-
cation electing to utilize epinephrine auto-injectors for emer-
gency medical aid to create a plan to address specified is-
sues. The Board supports AB 559. [A. Appr]
SB 633 (Sher), as amended April 19, 2001, the California
Mercury Reduction Act of 2001, would make findings that
mercury is a serious threat to public health and the environ-
ment and make several legislative changes aimed at restricting
the amount of mercury added to the environment. To reduce
the amount of mercury added to the environment by broken
and discarded fever thermometers, this bill would ban the manu-
facture, sale, or supply of mercury fever thermometers except
when the thermometer is supplied to a consumer or patient by
written prescription. Any thermometer supplied under prescrip-
tion must be accompanied by adequate instructions concern-
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ing proper handling and cleanup in case of breakage. [S. Appr]
SB 696 (Speier). Existing federal law establishes the
Medicare program, a national health insurance program for
people 65 years and older; Medicare does not cover outpa-
tient prescription drugs. To fill this void, and consistent with
the law in 14 other states, SB 696 would enact-contingent
on federal approvals-a voluntary Medicare drug rate pro-
gram providing prescription drugs at reduced prices to Medi-
care beneficiaries.
As amended April 17, 2001, SB 696 would enact the
Golden Bear State Pharmacy Assistance Program, participation
in which would be voluntary for Medicare beneficiaries, phar-
macies, and drug manufacturers. The bill would permit DHS to
negotiate rebate amounts with drug manufacturers, contingent
upon sufficient participation by the drug manufacturers. SB 696
would require pharmacies to charge prices based on specified
components, including rebates to be negotiated with drug manu-
facturers, and would require DHS to pay pharmacies an amount
based on these rebates. It would further require rebate amounts
paid by DHS with respect to a manufacturer's drug to also be
paid by the manufacturer to DHS.
SB 696 would require moneys received from drug manu-
facturers pursuant to the bill to be deposited into the Golden
Bear State Pharmacy Assistance Program Rebate Fund, which
would be created by the bill. The fund would be continuously
appropriated to DHS without regard to fiscal year for imple-
mentation of the bill. SB 696 would be implemented only
upon the receipt of all necessary federal approvals and if DHS
is able to negotiate a sufficient number of rebate agreements.
SB 696 would appropriate $1,000,000 from the general fund
to DHS in the form of a loan, for startup costs for implemen-
tation of the bill. [S. Appr]
LITIGATION
On February 6, 2001, in Western States Medical Center
v. Shalala, 283 F.3d 1090, the U.S. Ninth Circuit Court of
Appeals held that certain subsections of the Food and Drug
Administration Modernization Act of 1997 (FDAMA) that
restrict the advertising of compounded drugs violate first
amendment commercial speech rights. Further, the court held
that the advertising restrictions are not severable from the
remaining provisions of the statute and, therefore, the entire
statute is unconstitutional-thrusting pharmacy compound-
ing regulation into uncertainty (see MAJOR PROJECTS).
Compounding is the process by which a pharmacist com-
bines, mixes, or alters ingredients to specialize a medication
for a patient at the direction of a physician. One provision of
the FDAMA, 21 U.S.C. section 353a, recognized compound-
ing as an element of the practice of pharmacy that is to be
regulated by the states, and distinguished it from "manufac-
turing" (which falls within the jurisdiction of the FDA). The
1997 legislation exempted compounding from certain require-
ments of the federal Food, Drug and Cosmetic Act, but only
under certain conditions. Under the FDAMA, pharmacists
may advertise to the public that they offer general compound-
ing services, but may not advertise that they compound par-
ticular drugs. In this case, plaintiffs-a group of licensed
pharmacies-sought to enjoin enforcement of 21 U.S.C. sec-
tions 353a(a) and (c), arguing that a restriction on pharma-
cists' ability to advertise particular compounded drugs vio-
lates the first amendment.
In order to meet the test for acceptable government regu-
lation of commercial speech, as set forth in Central Hudson
Gas & Electric Corp. v. Public Service Commission, 447 U.S.
557 (1980), a regulation must satisfy a four-part test. The court
must determine whether: (1) the regulated speech is mislead-
ing or concerns unlawful activity; (2) the government has
asserted a "substantial" interest in restricting the speech; (3)
the government has demonstrated that the regulation "directly
advances" the asserted interest; and (4) the restriction is not
more extensive than necessary to achieve the asserted gov-
ernmental interest.
As to factor (1), the court found that the pharmacies'
advertising is not untruthful or misleading. On factor (2), the
Ninth Circuit agreed that the government has a substantial
interest protecting the public health and safety and preserv-
ing the integrity of the drug approval process. As to factor
(3), the government argued that the advertising restrictions
are necessary to prevent in increase in the demand for com-
pounded drugs that would be injurious to the public health.
Here, the Ninth Circuit held that the government failed to
offer evidence or arguments to explain sufficiently why those
restrictions will reduce the type of consumption of com-
pounded drugs that is harmful. The court noted that other safe-
guards exist to protect the public-for example, the require-
ment of a valid physician's prescription, limitations on the
substances that can be used to fashion a compounded drug,
and a prohibition on the compounding of drugs that are es-
sentially copies of commercially available drug products.
Further, the court said that "FDAMA is so riddled with
exceptions that it is unlikely that the speech restrictions would
actually succeed in depressing the volume of compounded
drugs. The exceptions also demonstrate that the restrictions
do not directly advance the government's interest in main-
taining the integrity of the drug approval process. Under the
statute, pharmacists can advertise their compounding services
and promote their skills at medical trade events so long as
they do not promote the compounding of any particular drug.
It seems obvious that advertising that informs physicians that
a pharmacy is available to compound drugs is likely to in-
crease demand for compounding. Moreover, even with the
ban on specific advertising, FDAMA provides significant in-
centives for pharmacies to increase their drug compounding
business. The statute allows compounded drugs to constitute
up to five percent of a pharmacy's interstate drug distribu-
tions and 100 percent of its intrastate drug distributions. If a
pharmacy has a Memorandum of Understanding with the
Secretary of Health and Human Services, up to twenty per-
cent of its interstate drug distributions can be in the form of
compounded drugs....Under FDAMA, a pharmacist can call
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a physician and recommend a drug compound when a patient
comes in with a prescription for a commercial drug and pro-
vides information to the pharmacist that indicates that the
patient might require a compounded product. When exemp-
tions and inconsistencies counteract the alleged purpose of a
speech restriction, the restriction fails the direct advancement
test" (emphasis original; citation omitted).
The court went on to find that the restrictions also fail
the fourth Central Hudson factor because they are more ex-
tensive than necessary to achieve the asserted government
interest. The court noted that the government could have re-
quired disclaimers on compounded drugs saying that they had
not been subject to FDA approval or could require safety re-
views similar to those required for manufactured drugs in
order to meet safety concerns.
Finally, the Ninth Circuit held that the challenged sub-
sections could not be severed from the rest of the statute be-
cause Congress would not have enacted the remaining provi-
sions of the FDAMA absent the advertising restrictions; thus
the entire statute is invalid. At this writing, the federal gov-
ernment plans to petition the U.S. Supreme Court for review
of the Ninth Circuit's decision.
In December 2000, a Sacramento County Superior Court
jury awarded former Board supervising inspector Labib Doumit
$3 million in damages in Doumit v. Board of Pharmacy, et al.,
No. 98AS04499. Doumit alleged that he was harassed by Board
Executive Officer Patricia Harris after he reported to federal
authorities his suspicions that his supervisors had mishandled
evidence and mismanaged a joint state-federal investigation
into Medi-Cal fraud. Further, he claimed that Harris and Assis-
tant Executive Officer Virginia Herold came to his home and
removed computer equipment, office supplies, and a Board
van-an incident that allegedly caused him angina for which
he was hospitalized and subsequently took a medical- leave.
Doumit claimed this treatment came in retaliation for report-
ing his suspicions to the U.S. Attorney's Office. Following a
trial, the jury awarded Doumit $1.4 million for past and future
lost wages, $850,000 for lost pension benefits, $250,000 for
invasion of privacy, and $500,000 for emotional distress.
At the Board's January 2001 meeting, Board President Rob-
ert Elsner stated that "the Board stands firmly behind its manag-
ers, Executive Officer Patricia Harris and Assistant Executive
Officer Virginia Herold, who made every effort to act lawfully
and to be fair and cordial in their relationship with Mr. Doumit
throughout his employment....The Board of Pharmacy will
appeal the jury's verdict and seek review of the legal basis for
the damages awarded in this case. The Board disagrees with the
jury's decision and continues to support its management."
RECENT MEETINGS
At its April 13, 2000 meeting, the Board elected Robert
Elsner as President, Steven Litsey as Vice-President, and
Caleb Zia as Treasurer.
At its July 25-26, 2000 meeting, the Board voted to ac-
knowledge the existence of a pharmacist shortage in Califor-
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nia, and directed its Licensing Committee to work with in-
dustry in an effort to find solutions. At its October 2000 meet-
ing, the Board convened a task force to seek solutions to the
pharmacist shortage. The task force will consist of the two
Licensing Committee members and approximately 15 mem-
bers as recommended by the Committee and appointed by
the Board President and Vice-President.
In October 1998, the Board's counsel recommended that
the Board consider proposed legislation that would authorize
the Board to issue "site" permits to pharmacies owned by a
limited liability company (LLC). [16:1 CRLR 70-71] At that
time, the Board accepted this recommendation and initiated
efforts to introduce legislation but never obtained an author. At
its October 2000 meeting, the Board took the opposite stance
and unanimously voted not to license any pharmacy as an LLC.
At the Board's January 2001 meeting, Board member Holly
Strom reported on a longstanding request of the Hoopa Indian
Tribe for a waiver of the Board's licensure requirements so
that a pharmacy could be located on tribal ground to serve both
members of the tribe and California residents from outside the
tribe. Although a pharmacy operated on tribal lands is not re-
quired to comply with California pharmacy law for the pur-
pose of serving residents of the reservation, a California li-
cense is required if the pharmacy also serves other California
residents. The Hoopa Tribe has been unable to hire a Califor-
nia-licensed pharmacist, and has sought a waiver of the re-
quirement for a California pharmacist-in-charge under Busi-
ness and Professions Code section 4118; however, the Board
believes it is not authorized to waive that particular require-
ment. Strom noted the pendency of AB 108 (Strom-Martin),
which would authorize the Board to issue a license to a phar-
macy with a pharmacist-in-charge who is licensed in another
state (see 2001 LEGISLATION). Under AB 108, the Hoopa
Tribe would be able to hire non-licensed pharmacists. Board
members expressed concern that if such a waiver were allowed,
the Board would not have jurisdiction over the non-licensed
pharmacists, and would be unable to take action against viola-
tions committed by these pharmacists. In view of these con-
cerns, the Board voted unanimously to oppose AB 108.
At its April 25-26, 2001 meeting, the Board said fare-
well to Deputy Attorney General Bill Marcus, its longtime
liaison with the AG's Office; due to health problems, Marcus
retired after a long and distinguished career in state service.
Also in April, the Board elected Steven Litsey as President,
John Jones as Vice-President, and Caleb Zia as Treasurer.
FUTURE MEETINGS
2001: July 25-26 in San Diego; October 15-16 in San
Francisco.
2002: January 23-23 in Los Angeles; April 24-26 in Sac-
ramento; July 24-25 in San Diego; October 23-24 in San
Francisco.
2003: January 22-23 in Los Angeles; April 9-10 in Sac-
ramento; July 21-22 in San Diego; October 29-30 in San
Francisco.
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